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Abstract
T47D and MCF7 are two human hormone-dependent breast cancer cell lines which are widely used as experimental models
for in vitro and in vivo (tumor xenografts) breast cancer studies. Several proteins involved in cancer development were
identified in these cell lines by proteomic analyses. Although these studies reported the proteomic profiles of each cell line,
until now, their differential protein expression profiles have not been established. Here, we used two-dimensional gel and
mass spectrometry analyses to compare the proteomic profiles of the two cell lines, T47D and MCF7. Our data revealed that
more than 164 proteins are differentially expressed between them. According to their biological functions, the results
showed that proteins involved in cell growth stimulation, anti-apoptosis mechanisms and cancerogenesis are more strongly
expressed in T47D than in MCF7. These proteins include G1/S-specific cyclin-D3 and prohibitin. Proteins implicated in
transcription repression and apoptosis regulation, including transcriptional repressor NF-X1, nitrilase homolog 2 and
interleukin-10, are, on the contrary, more strongly expressed in MCF7 as compared to T47D. Five proteins that were
previously described as breast cancer biomarkers, namely cathepsin D, cathepsin B, protein S100-A14, heat shock protein
beta-1 (HSP27) and proliferating cell nuclear antigen (PCNA), are found to be differentially expressed in the two cell lines. A
list of differentially expressed proteins between T47D and MCF7 was generated, providing useful information for further
studies of breast cancer mechanisms with these cell lines as models.
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Introduction
Breast cancer is the most frequent cancer affecting women. The
malignancy accounts for about 1 in 10 cancers in the world and is
diagnosed in one million women each year [1,2]. In North
America (United States and Canada), breast cancer is the second
most frequent cause of cancer death in women, after lung cancer,
and the leading cause of cancer death among those aged 20–59
years old [3,4]. After increasing through the 80 s and 90 s, breast
cancer incidence rates fortunately decreased by 3.5% per year
from 2001 to 2004 and the mortality rate decreased by 1.9% per
year in the United States between 1998 and 2006 [3,4]. This
reflects an improvement in the diagnosis and treatment of the
disease, but this cancer nonetheless remains of prime importance.
Human breast cancer cell lines provide an excellent platform for
breast cancer research in tumor progression and treatment. T47D
and MCF7 are two human hormone-dependent breast cancer cell
lines which are widely used as experimental models for breast
cancer studies. The two cell lines were generally used for both the
in vitro (in cell culture) and in vivo (tumor xenograft in nude mice)
analyses of gene and protein function and inhibitor efficacy
assessment [5–7]. They were both originally derived from a
metastatic site of pleural effusion (ATCC, www.atcc.org) and
express estrogen receptors. Several proteins and enzymes that are
involved in cell proliferation and in cancer development were
identified in these cell lines by proteomic studies [8–10]. Although
these studies reported the proteomic profiles of each of these cell
lines, until now, no study had established their differential protein
expression profile. Using a proteomic approach including two-
dimensional (2-D) gel electrophoresis and mass spectrometry (MS)
analyses, we establish here the proteomic differences between the
T47D and MCF7 cell lines.
Methods
Cell culture
T47D and MCF7 cells were obtained from the American Type
Culture Collection (ATCC, Manassas, VA). MCF7 cells were
maintained in DME low glucose medium supplemented with
1n Mb-estradiol (b-E2). T47D cells were propagated in DME
high glucose medium containing 7.5 mg/L bovine insulin (Sigma,
Oakville, Ontario, Canada). Both cell types were cultured in
phenol red-free media containing 10% fetal bovine serum (FBS)
and incubated at 37uC in a humidified atmosphere of 95% air and
5% CO2.
Generation of protein extracts for proteomics analysis
MCF7 and T47D cells were cultured in T75 flasks in com-
plete growth medium. After three passages, cells were plated
in 10062 cm2 dishes and cultured until reaching 80–90%
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scraped with a policeman in 1.2 mL PBS, collected in an
eppendorf and centrifuged at 3000 rpm for 5 min. The cell pellets
were resuspended in 500 ml lysis buffer T8 (7 M urea, 2 M
thiourea, 3% CHAPS, 20 mM DTT, 5 mM TCEP, 0.5% IPG
buffer pH 4–7, 0.25% IPG buffer pH 3–10) containing 50 mM
tris-HCl pH 8.8, 1 mM PMSF and 1% protease inhibitors cocktail
(EMD Chemicals, Gibbs-town, NJ). Protein samples were
precipitated using 2-D Clean-Up Kit (GE Healthcare, Piscataway,
NJ) and resolubilized in T8 buffer. Protein samples included three
independent biological replicates (coming from three independent
cell culture experiments), representing total proteins from each cell
line (MCF7 and T47D) for a total of six samples. The protein
concentrations were determined using the 2-D Quant Kit (GE
Healthcare).
Two-dimensional gel electrophoresis
For the first dimension, 200 mg total protein samples from
MCF7 and T47D cell lines were loaded onto 24-cm pH 4–7
Immobilized pH gradient (IPG) strips (Immobiline DryStrips; GE
Healthcare). Strips were rehydrated for 10 hours at 30 volts and
isoelectric focusing was performed on an IPGphorII IEF system
(GE Healthcare). For the second-dimension SDS-PAGE, focused
Immobiline DryStrips were equilibrated twice for 15 min in an
equilibration buffer (50 mM tris-HCl pH 8.8, 6 M urea, 30%
glycerol, 2% SDS, trace of bromophenol blue) containing 10 mg/
mL DTT for the first equilibration and 25 mg/mL iodoacetamide
for the second one. Immobiline DryStrips were then transferred
onto the surface of a 12% acrylamide gel and sealed using 0.5%
agarose. Gels were run in Ettan DALTtwelse system (GE
Healthcare) in a standard tris-glycine SDS-PAGE buffer at
40 mA/gel and 15uC until the tracking dye reached the end of
the gel. Three independent protein samples coming from three
independent cell culture experiments were run for each cell line.
Gels were fixed overnight in 40% methanol, 7% acetic acid,
stained with Sypro Ruby (Invitrogen, Burlington, Ontario,
Canada) and scanned with the ProXpress CCD scanner
(PerkinElmer, Waltham, MA). The 2-D gel electrophoresis was
performed at the Proteomic platform of the Infectious Disease
Research Center (Quebec, Canada).
Two-dimensional gel image analysis
Protein spot detection, spot matching and semiquantitative
statistical analysis were performed using the Progenesis software
version PG240 (Nonlinear Dynamics, Durham, NC). For each cell
line, three different gel images were analysed and a corresponding
synthetic image reference was obtained. After computer matching,
detected spots and spot matches were manually edited for more
Figure 1. Proteomic analysis of T47D and MCF7 cells using 2-D gels and mass spectrometry. (A) Representative 2-D gel images for T47D
and MCF7 cells showing some differentially expressed spots. The 2-D gels were scanned and the differentially expressed (2-fold or higher, p,0.05)
proteins were detected using Progenesis software. Arrows indicate some identified protein spots picked for MS analysis. The numbers refer to the
spot number listed in Table 1 and 2. Spot numbers 2685, 2879 and 4364 were unique in either cell line whereas spot numbers 2903 and 4375 were
up-regulated in one cell line compared to the other cell line. 1 and 2 represent two different regions of the entire 2-D gel images. (B) Summary of the
numbers of spots and proteins obtained from the 2-D gel and mass spectrometry analyses of T47D and MCF7. * Up-regulated (up) and down-
regulated (down) proteins in T47D cell line as compared to MCF7 cell line.
doi:10.1371/journal.pone.0031532.g001
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Spot FC Description
UniProt
number
MW exp/
pred (kDa)
pI
exp Pep
Function description and/or
biological process
2810 3.0 Phosphoserine phosphatase P78330 26/25 5.4 15 Serine biosynthesis
Uncharacterized protein EIF4E (Fragment) A8MX72 26/25 5.4 5 Protein biosynthesis
cDNA FLJ76387…arginine/serine-rich 9… A8K3M9 26/26 5.4 5 Nucleic acid binding
Transmembrane emp24 domain-containing prot. 7 Q9Y3B3 26/25 5.4 5 Transport
Heat shock protein beta-1{ (2873,2808,4439) P04792 26/23 5.4 3 Stress resistance, actin organization
Peroxiredoxin-4 Q13162 26/31 5.4 2 Redox regulation of the cell
2490 6.1 P09493-3 Isoform 3 of P09493 P09493-3 32/33 4.6 38 Muscle contraction
Proliferating cell nuclear antigen*{ P12004 32/29 4.6 16 DNA replication
2682 2.1 Protein CDV3 homolog* (2658,2399) Q9UKY7 28/27 5.4 6 Cell proliferation
N(G),N(G)-dimethylarginine dimethylaminohydrolase 2 O95865 28/30 5.4 5 Anti-apoptosis, arginine catabolism
Prohibitin (2674,4384) P35232 28/30 5.4 5 DNA synthesis, cell proliferation
2869 3.2 Glutathione S-transferase Mu 2 P28161 25/26 6.1 53 Metabolic process
59(39)-deoxyribonucleotidase, cytosolic type Q8TCD5 25/23 6.1 25 Nucleotide metabolism
17b-Hydroxysteroid dehydrogenase 10* Q5H927 25/26 6.1 6 Oxidoreductase - metabolism
Protein-L-isoaspartate(D-aspartate) O-methyltransferase P22061 25/25 6.1 4 Protein methylation, protein repair
2903 4.3 Cathepsin B*{ P07858 24/38 5.1 4 Tumor invasion and metastasis
Heat shock protein 75 kDa, mitochondrial Q12931 24/80 5.1 3 Chaperone
2399 3.0 Nicotinate-nucleotide pyrophosphorylase Q15274 35/31 5.8 9 Pyridine nucleotide biosynthesis
Malate dehydrogenase, cytoplasmic P40925 35/36 5.8 4 Gluconeogenesis
L-lactate dehydrogenase A chain P00338 35/37 5.8 4 Glycolysis
Farnesyltranstransferase O95749 35/35 5.8 4 Isoprene biosynthesis
Splicing factor, arginine/serine-rich 1 Q07955 35/28 5.8 3 mRNA processing
STIP1 homology and U box-containing protein 1 Q9UNE7 35/35 5.8 3 Chaperone activity modulation
Heterogeneous nuclear ribonucleoproteins A2/B1 P22626 35/37 5.8 3 Pre-mRNA processinghttp://www.
uniprot.org/keywords/KW-0508
39S ribosomal protein L3, mitochondrial P09001 35/39 5.8 2 Translation
2685 U Cathepsin D{ (2658,2873,2674,2682,4384,4375,1968) P07339 28/45 5.0 20 Proteolysis
cDNA, FLJ92320, highly similar to Homo sapiens
glutathione S-transferase theta 2 (GSTT2), mRNA
B2R533 28/28 5.0 5 Transferase
Uncharacterized protein PSME2 (2682,2674,4384) A8MZ76 28/29 5.0 4 Proteasome activation
Inositol monophosphatase P29218 28/30 5.0 5 Phosphatidylinositol biosynthetis
Chloride intracellular channel protein 1 O00299 28/27 5.0 3 Ion transport
Density-regulated protein O43583 28/22 5.0 2 Translation initiation
2879 U Heat shock 70 kDa protein 1 (HSP70.1)* P08107 25/70 5.2 4 Stress response, polypeptide folding
A-kinase anchor protein 3 O75969 25/95 5.2 2 Capacitation and acrosome reaction
2508 U Caspase-3 subunit p12 P42574 32/32 6.2 14 Apoptosis
Nuclear protein Hcc-1 P82979 32/24 6.2 5 Cell growth, carcinogenesis
Guanine nucleotide-binding protein subunit
beta-2-like 1
P63244 32/35 6.2 4 Regulation of the activity of
kinases, tissue differentiation
G1/S-specific cyclin-D3 P30281 32/33 6.2 4 Cell cycle control
ATP synthase subunit gamma, mitochondrial P36542 32/33 6.2 3 ATP synthesis, ion transport, transport
Carbonyl reductase [NADPH] 1 P16152 32/30 6.2 2 Catalysis of reduction
Electron transfer flavoprotein subunit alpha, mitochondrial P13804 32/35 6.2 2 Electron transport
Voltage-dependent anion-selective channel protein 1 P21796 32/31 6.2 2 Apoptosis, host-virus interaction,
transport
Pyrroline-5-carboxylate reductase A6NFM2 32/33 6.2 2 Amino-acid biosynthesis
Cell division control protein 2 homolog P06493 32/34 6.2 2 Cell cycle control (s-phase, mitosis)
2,4-dienoyl-CoA reductase, mitochondrial Q16698 32/36 6.2 2 Oxidoreductase
Elongation factor Ts, mitochondrial P43897 32/35 6.2 2 Protein biosynthesis
cDNA FLJ76011, highly similar to Homo sapiens lactamase, beta 2
(LACTB2), mRNA
A8K2D6 32/33 6.2 2 Hydrolase activity
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replicate gels to be considered in the analysis. The detection
of protein spots differentially expressed was performed using the t-
test and INCA volume and proteins that were differentially
expressed 2-fold or higher were considered significant. 40 protein
spots that were differentially expressed were selected and were
excised from Sypro Ruby-stained 2-D gels using a ProXcision
robot (PerkinElmer) and sent for MS analysis.
Mass spectrometry and protein identification
MS experiments were performed by the Proteomics platform
of the Eastern Quebec Genomics Center (Quebec, Canada).
Protein spots were washed with water and tryptic digestion was
performed on a MassPrep liquid handling robot (Waters, Milford,
MA) according to the manufacturer’s specifications and to the
protocol of Shevchenko et al [11] with the modifications
suggested by Havlis et al [12]. Peptide samples (an aliquot of
the digested proteins) were separated by online reversed-phase
(RP) nanoscale capillary liquid chromatography (nanoLC) and
analyzed by electrospray mass spectrometry (ES MS/MS). The
experiments were performed with a Thermo Surveyor MS pump
connected to a LTQ linear ion trap mass spectrometer
(ThermoFisher, San Jose, CA) equipped with a nanoelectrospray
ion source (ThermoFisher). Peptide separation took place on a
PicoFrit column BioBasic C18, 10 cm60.075 mm internal
diameter (New Objective, Woburn, MA) with a linear gradient
from 2–50% solvent B (acetonitrile, 0.1% formic acid) in
30 minutes, at 200 nL/min (obtained by flow-splitting). Mass
spectra were acquired using a data dependent acquisition mode
using Xcalibur software version 2.0. Each full scan mass spectrum
(400 to 2000 m/z) was followed by collision-induced dissociation
of the seven most intense ions. The dynamic exclusion (30 sec
exclusion duration) function was enabled, and the relative
collisional fragmentation energy was set to 35%.
All MS/MS samples were analyzed using Mascot algorithm
(Matrix Science, London, UK; version Mascot) and the Uni-
ref100_14_0_Homo_sapiens_9606 database (version with 89892
entries). Mascot was searched with a fragment ion mass tolerance
of 0.50 Da and a parent ion tolerance of 2.0 Da. Iodoacetamide
derivative of cysteine was specified as a fixed modification and
oxidation of methionine was specified as a variable modification.
Two missed cleavages were allowed. Scaffold (version Scaf-
fold_2_01_02, Proteome Software Inc., Portland, OR) was used
to validate MS/MS based peptide and protein identifications. The
protein identification cut off was set at a confidence level of 95%
(MASCOT score .33) with at least two peptides matching to a
protein. Proteins that contained similar peptides and could not be
differentiated based on MS/MS analysis alone were grouped to
satisfy the principles of parsimony.
Functional analysis of the identified proteins
From each spot, only proteins identified with a probably higher
than 95% and with at least two matched unique peptides were
considered in the analysis, except for the proteins keratins which
were not considered for the analysis. The experimental molecular
weight and isoelectric point of each identified protein were
determined based on the location of the original spot on the 2-D
gel using the Progenesis software. The Uniprot data base (www.
uniprot.org) was used to search the function/biological process
and the subcellular location of each identified protein. Search in
the literature (Pubmed) was used when necessary to complete the
information about the function and subcellular location.
Quantitative real-time RT-PCR
Total RNAs were isolated from T47D and MCF7 cells using
Trizol Reagent (Invitrogen) in 6-well plates and treated with
DNase 1. RNA samples for Q-RT-PCR analyses comprised two
biological repetitions for each cell line. The measures of mRNA
levels of genes were carried out as previously described [7,13] with
Atp5o, Hprt1 and G6PD genes used as internal controls. The
procedures were performed at the Q_RTPCR Platform service at
CHUQ-CHUL Research Center (Quebec, Canada). The mRNA
levels were expressed as thousand of mRNA copies/mg total RNA
and SDs were ,10% of duplicates.
Results
The proteome comparison of T47D and MCF7 cells
To compare the proteomes of T47D and MCF7 cells, we
performed 2-D gel analysis using total protein lysates of the two
cell lines. The analysis was carried out on six 2-D electrophoresis
gels made from three independent protein samples of each cell
line. The Progenesis Discovery software package was used to carry
out statistical comparative analyses of the proteomic profiles of
T47D and MCF7 cells. The two cell lines displayed similar spot
patterns, which allowed a good spot alignment (Figure 1A). T47D
protein samples exhibited 298 supplementary spots compared to
MCF7 (Figure 1B), suggesting that the former cells express a
higher number of proteins than the latter. The proteomic analyses
using the Progenesis software and a t-test (with a p-value,0.05)
identified 97 significant differential spots as follows: 70 spots
exhibited a variation$2-fold, including 31 spots up-regulated and
39 spots down-regulated in T47D, whereas 12 and 15 spots were
found unique to T47D and MCF7, respectively (Figure 1B). Some
differentially expressed spots are shown in more detail in
Figure 1A.
For the next step, MS identification, protein spots were selected
among those uniquely and strongly (more than 3-fold difference)
overexpressed, but also among those weakly (2 to 3-fold difference)
up-regulated and well defined in each cell. The selection of weakly
up-regulated spots was relevant to detect small proteomic
differences between cells. A total of 40 spots were excised from
Sypro Ruby-stained 2-D gels and were subjected to trypsin
digestion. The resulting peptide fragments were analyzed by MS.
Proteins with known UniProt accession numbers were identified in
all the 40 spots. The numbers of proteins revealed by MS analysis
are listed in Figure 1B. A total of 205 proteins were identified from
The function description and/or biological process were from the UniProt database (www.uniprot.org). Spot, spot number; FC, fold change; MW, molecular weight; pI
exp, isoelectric point as determined from the 2-D gel experiments; Pep, number of unique peptides; U, unique. The number after the protein name indicated the
additional spot in which the protein was found.
{Proteins previously reported to be used as breast cancer biomarkers and which were overexpressed in cancerous cells based on data from the literature [10,14,15].
*Proteins used for Q-RT-PCR validation.
doi:10.1371/journal.pone.0031532.t001
Table 1. Cont.
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Spot FC Description
UniProt
number
MW exp/
pred (kDa)
pI
exp Pep
Function description and/or
biological process
2808 3.2 Triosephosphate isomerase P60174 28/27 6.2 19 Fatty acid biosynthesis, glycolysis
Protein ETHE1, mitochondrial O95571 28/28 6.2 2 Suppression of p53-induced apoptosis
2212 2.0 Heterogeneous nuclear ribonucleoprotein H3(4375) P31942 42/37 6.5 13 mRNA processing
Aflatoxin B1 aldehyde reductase member 2 O43488 42/40 6.5 8 Cellular aldehyde metabolism
Glycerol-3-phosphate dehydrogenase 1-like Q8N335 42/38 6.5 6 Glycerol-3-phosphate catabolism
Heterogeneous nuclear ribonucleoprotein D-like O14979 42/46 6.5 2 Transcription regulation
4384 5.2 Latexin Q9BS40 31/26 5.5 14 Metalloendopeptidase inhibition
Proteasome activator complex subunit 1 Q06323 31/29 5.5 4 Immunoproteasome assembly
cDNA, FLJ96310 (2674,2617,4375,4384) B2RCV1 31/33 5.5 2 Transport
4375 11 cDNA, FLJ94267, highly similar to Homo sapiens
glutathione S-transferase (3184)
B2R983 32/28 6 16 Metabolism
NAD-dependent deacetylase sirtuin-3, mitoch. Q9NTG7 32/44 6 2 NAD-dependent deacetylase activity
3427 3.3 SH3 domain-binding glutamic acid-rich-like O75368 17/13 5.2 14 Sh3 domain binding, sh3/sh2 adaptor
3184 2.7 Myosin regulatory light chain 2, nonsarcomeric P19105 21/20 4.6 7 Cytokinesis, receptor capping, cell
locomotion
3405 2.4 Profilin (3102) Q4VBQ4 21/15 4.6 12 Actin binding
Cellular retinoic acid-binding protein 1 P29762 21/16 4.6 2 Transport
TRM112-like protein Q9UI30 21/14 4.6 2 Protein binding
3102 2.2 Chromobox protein homolog 3* (3095) Q13185 21/21 5.1 11 Transcription regulation
BH3-interacting domain death agonist p11 P55957 21/22 5.1 2 Apoptosis
Chromobox protein homolog 5 P45973 21/22 5.1 2 Repressor of transcription, chromatin
assembly or disassembly
3095 7.0 Cytochrome c-releasing factor 21* O75223 23/21 5.0 5 Induction of apoptosis
1968 4.7 Interleukin-10 P22301 50/21 5.0 2 Inhibits the synthesis of cytokines, B
cell proliferation, anti-apoptosis
Telomerase-binding protein EST1A Q86US8 50/160 5.0 2 Telomere regulation, nonsense-
mediated mRNA decay
Bullous pemphigoid antigen 1, isoforms 6/9/10 O94833 50/591 5.0 2 Cell adhesion
cAMP response element-binding protein P16220 50/37 5.0 2 Host-virus interaction, transcription
Coiled-coil domain-containing protein 110 Q8TBZ0 50/97 5.0 2 Unknown
CHD9 protein B2RTU2 50/326 5.0 2 Transcription, transcription regulation
1870 5.7 Transcriptional repressor NF-X1 Q12986 53/124 5.1 2 Transcription regulation
MHC class I antigen (Fragment) A2TEM8 53/11 5.1 2 Immune response
Probable global transcription activator SNF2L2 B1ALG3 53/181 5.1 2 Transcriptional coactivator
cooperating with nuclear hormone
receptors
4439 U Thioredoxin-dependent peroxide reductase, mitochondrial(2887) P30048 25/28 6.2 2 Redox regulation of the cell
4492 U Transgelin-2 P37802 20/22 5.6 8 Muscle development
4404 U Pyridoxine 5’-phosphate oxidase (F.) Q53FP0 29/30 5.8 5 Pyridoxine biosynthesis
Isopentenyl-diphosphate Delta-isomerase 1 Q13907 29/26 5.8 4 Steroid, lipid, carotenoid biosynthesis
3563 U Calcyphosin Q13938 23/21 4.6 10 Regulation of ionic transport
4572 U Protein S100-A14{ Q9HCY8 16/12 5.0 4 Calcium ion binding
4530 U Calmodulin-like 5 Q5SQI3 18/16 4.2 4 Calcium ion binding
4094 U NADP-dependent malic enzyme P48163 75/64 5.8 24 Nadp biosynthetic process
T-complex protein 1 subunit alpha P17987 75/60 5.8 12 Protein folding
Prolyl 4-hydroxylase subunit alpha-1 P13674 75/61 5.8 10 Protein metabolic process
Heterogeneous nuclear ribonucleoprotein K P61978 75/51 5.8 5 Host-virus interaction,mRNA
processing
Beta-galactosidase A8MZ11 75/73 5.8 3 Glycosidase, hydrolase
REST corepressor 1 Q9UKL0 75/53 5.8 2 transcription transcription regulation
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example, nitrilase homolog 2 was found in only one spot, the spot
number 4364, while cathepsin D was found in several spots
including spot numbers 2685 (Figure 1A). Consequently, distinct
proteins amount to 164 with 52 and 16 proteins from spots
unique to T47D and MCF7, respectively, and 96 proteins from
Figure 2. Functions and cellular locations of the differentially expressed proteins in T47D and MCF7 cells identified by the
proteomics approach. The Uniprot database was used to generate the cellular location and the molecular function and/or biological process of each
of the 164 non-redundant (distinct) proteins identified by mass spectrometry analysis as differentially regulated in T47D as compared to MCF7 cells.
doi:10.1371/journal.pone.0031532.g002
Spot FC Description
UniProt
number
MW exp/
pred (kDa)
pI
exp Pep
Function description and/or
biological process
4364 U Nitrilase homolog 2* Q9NQR4 32/31 5.9 4 Decreases the colony-forming
capacity of cultured cells by arresting
cells in the G2 phase of the cell cycle
The function description and/or biological process and the subcellular location were from the UniProt database (www.uniprot.org). Spot, spot number; FC, fold change;
MW, molecular weight; pI exp, isoelectric point as determined from the 2-D gel experiments; Pep, number of unique peptides; U, unique. The number after the protein
name indicated the additional spot in which the protein was found.
{Protein previously reported to be used as a breast cancer biomarker and which were overexpressed in cancerous cells based on data from the literature [9,10].
*Protein used for Q-RT-PCR validation.
doi:10.1371/journal.pone.0031532.t002
Table 2. Cont
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cells present some significant differences in regard to their
proteomes.
Functional and subcellular protein categorizations
Using the UniProt database at www.uniprot.org, we determined
the functions and/or biological processes of each identified protein
(Table 1, 2 and S1). Table 1 and Table S1 list the proteins found
in spots up-regulated or unique to T47D as compared to the
MCF7 cell line while Table 2 lists the proteins found in spots
down-regulated in T47D or unique to MCF7. The spot from
which each protein was identified, the spot fold-increase or fold-
decrease in one cell line versus the other cell line, the protein name,
the molecular weight, the isoelectric point, the number of unique
peptides allowing the identification of each protein in the MS
analysis, and the UniProt accession number of the protein, were
mentioned. The information about the molecular function and/or
biological process and subcellular location was found for most
proteins. The repartition of each function and subcellular location
are illustrated in Figure 2. From the 164 proteins identified by MS,
14 were principally implicated in transport, 13 in metabolism, 11
in apoptosis, 9 in proteolysis, 8 in transcription, 7 in mRNA
processing and 7 in RNA and protein binding. Differentially
expressed proteins are mainly located in cytoplasm and nucleus.
The proteomic comparisons notably led to the identification of
five proteins that are used as breast cancer diagnostic and
prognostic biomarkers: proliferating cell nuclear antigen (PCNA),
cathepsin D, cathepsin B, protein S100-A14, and heat shock
protein beta-1 (HSP27) [9,10,14,15] (Table 1 and 2). PCNA was
identified in a spot 6.1 times up-regulated in T47D, as compared
to MCF7. Cathepsin D was found in eight different spots, whereas
cathepsin B was found in a unique spot up-regulated in T47D as
compared to MCF7, and protein S100-A14, in a spot unique to
MCF7 as compared to T47D. HSP27 was found in four different
spots: two are overexpressed in T47D and two are overexpressed
in MCF7. These results showed that breast cancer biomarkers are
differentially expressed in the two breast cancer cell lines.
Comparison of protein and transcript expression
Next, we investigated the mRNA expression of proteins
identified in the proteomic analyses to evaluate if there is a
correlation between protein and mRNA expression. To do this,
eight proteins principally involved in steroid metabolism, cell
proliferation and apoptosis were selected: 17b-HSD type 10,
PCNA, cathepsin B, nitrilase homolog 2, CDV3 homolog, heat
shock 70 kDa protein 1 (HSP70.1), chromobox protein homolog 3
and cytochrome c-releasing factor 21. Their mRNA levels were
quantified by quantitative real-time RT-PCR (Q-RT-PCR)
analysis of total RNA extracts from the two cell lines T47D and
MCF7. Proteomics and Q-RT-PCR data were considered to
correlate if the mRNA level and protein spot were regulated in the
same direction (Table 3). Except for one protein, all the other
seven proteins for which the mRNA expression was evaluated,
exhibited a regulation in the same direction at protein and mRNA
levels in T47D as compared to MCF7. These data can indicate the
existence of a semiquantitative correlation between protein and
mRNA expression. Thus, it may be possible to predict the
presence of a protein based on its gene expression and inversely.
In parallel work, we also measured mRNA levels of various
proteins involved in estradiol (E2) synthesis, inactivation and
Table 3. Q-RT-PCR values (thousand copies of mRNA/mg total RNA) of mRNAs encoding various enzymes involved in estradiol
production (or action) and breast cancer cell proliferation within T47D and MCF7 and comparison with 2-D gel data.
Description T47D MCF7 Correlation 2-D gel and Q-RT-PCR
Proliferating cell nuclear antigen (PCNA)
* 2,333 1,600 Yes
Protein CDV3 homolog 592 419 Yes
17b-HSD type 10 1,740 1,477 Yes
Cathepsin B 1,425 1,255 Yes
Heat shock 70 kDa protein 1 (HSP70.1) 725 1,926 No
Chromobox protein homolog 3 1,321 1,966 Yes
Cytochrome c-releasing factor 21 19 29 Yes
Nitrilase homolog 2 435 791 Yes
17b-HSD type 1 697 83 nd
17b-HSD type 2 N N nd
17b-HSD type 5 4 850 nd
17b-HSD type 7 150 159 nd
17b-HSD type 12 362 101 nd
Aromatase (P450arom) 0 N nd
Estrogen sulfotransferase (EST) 0 0 nd
Steroid sulfatase (STS) 60 80 nd
Estrogen receptor alpha (ERa) 190 653 nd
Estrogen receptor beta (ERb)8 7 n d
Androgen receptor (AR) 127 96 nd
N, negligible (Q-RT-PCR values ,1 thousand copies of mRNA/mg total RNA); 0, mRNA not detected after many rounds of amplification; nd, not determined. SDs were
,10% of duplicates.
*Proteins in bold were selected for Q-RT-PCR validation after their identification by mass spectrometry analysis of 2-D gel spots.
doi:10.1371/journal.pone.0031532.t003
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several 17b-hydroxysteroid dehydrogenase (17b-HSD) enzymes
and steroid receptors (Table 3). Results showed that mRNAs of
17b-HSDs types 1 and 12 and androgen receptor (AR) are
expressed in greater amounts in T47D than in MCF7, whereas
mRNAs of 17b-HSD type 5, estrogen receptor alpha (ERa) and
steroid sulfatase are less expressed. The major difference however
concerned the transcript of 17b-HSD type 5 which was 189 times
lower in T47D than in MCF7. 17b-HSD type 7 was expressed at
about the same level in both cell lines while mRNA levels of 17b-
HSD type 2, aromatase and estrogen sulfotransferase were
negligible or near zero in both cell lines (Table 3). These data
show that the transcripts of enzymes and steroid receptors involved
in E2 production and action are differentially expressed in the two
cell lines. The correlation between protein and mRNA expression
was not determined for these enzymes since they were not
identified in the proteomic analyses.
Discussion
T47D and MCF7 cells are two ER positive hormone-dependent
breast cancer cell lines which additionally express AR. The two
cell lines are widely used for the studies of breast cancer
mechanisms. Proteomic studies of individual cell lines have been
previously reported [8–10] but the present study established the
first protein profile comparison between the two cell lines. The
overlaid 2-D gel images of T47D and MCF7 showed similar spot
patterns, reflecting their common origin, pleural effusion from
mammary gland tumor metastasis (ATCC, www.atcc.org). Pro-
teomic data suggest that T47D expresses a higher number of
proteins than MCF7; in agreement with the understanding of cell
evolution, this indicated that the first cell line could exhibit a
higher number of functional mRNAs and/or more active proteins
than the latter cell line.
MS analyses indicated that 18 proteins (Table 1, 2 and S1) were
present in more than one spot on the gel. These proteins included
heat shock protein beta-1 (implicated in stress resistance),
prohibitin (implicated in cell proliferation), chromobox protein
homolog 3 (implicated in transcription regulation) and cathepsin D
(implicated in proteolysis). For example, cathepsin D was found in
eight spots of which five were up-regulated and three were down-
regulated in T47D. The presence of a protein in several spots and
its regulation in different directions among the spots can be due to
post-translational modifications like phosphorylation, glycosyla-
tion, or limited proteolytic cleaveage [8]. The up-regulated
cathepsin D in T47D exhibited an apparent molecular weight
(MW) of about 28 kDa (25, 28 and 29 kDa), whereas the down-
regulated comprised a protein exhibiting a MW of 31–32 and
50 kDa. The presence of cathepsin D with several apparent MW
reflects the existence of isoforms. In fact, human cathepsin D is
synthesized as pre-pro-enzyme that undergoes a co-translational
removal of peptide and several proteolytic cleavages to generate
the pro-enzyme (a 52 kDa pro-cathepsin D), an enzymatically
active 44–48 kDa intermediate and a two-chain form with non-
covalently associated subunits of 14 and 31–34 kDa [8,16,17]. The
up-regulation of the 28 kDa isoform and the down-regulation of
the 50 kDa protein in T47D cells may indicate that the pro-
cathepsin D is down-regulated in this cell line. This may explain
why a cathepsin D with a MW higher than 33 kDa was not
identified in a previous T47D and antiestrogen-resistant derivative
T47D-r study [8].
Several proteins involved in cell growth and anti-apoptosis
regulations and cancerogenesis are more strongly expressed in
T47D than in MCF7. These proteins include caspase-3 subunit
p12, Nuclear protein Hcc-1, G1/S-specific cyclin-D3, cathepsin B,
protein CDV3 homolog, N(G),N(G)-dimethylarginine dimethyla-
minohydrolase 2 and prohibitin. Other proteins implicated in
transcription repression and apoptosis regulation are, on the
contrary, less abundantly expressed in T47D than in MCF7.
These are chromobox protein homologs 3 and 5, BH3-interacting
domain death agonist p11, cytochrome c-releasing factor 21,
transcriptional repressor NF-X1, nitrilase homolog 2 and
interleukin-10. From these data, it appears that proteins implicated
in cell proliferation stimulation seem to be more up-regulated in
T47D as compared to MCF7, whereas proteins involved in cell
growth regression are therein down-regulated. Our study showed
that proteins that are differentially expressed between T47D and
MCF7 are implicated in all the biological functions of the cell. An
example is ‘DNA replication’ which contributes to cell prolifer-
ation. In addition, markers classified as risk markers (genetic),
prognostic factors (which correlate with patient outcome),
predictive markers (prediction of the response or resistance to a
specific therapy) and markers for the follow-up of patients with
diagnosed cancer (recurrent disease detection or treatment
monitoring) [9,10,14,15] are found to be differentially expressed
in the two cell lines. Most of these markers have been tested on
tumor samples, and they are overexpressed or mutated in a
significant proportion of breast cancers. The best-known molec-
ular risk marker is PCNA [14].
Estrogens are clearly carcinogenic in humans but the molecular
pathways by which these hormones induce cancer are only
partially understood [18]. To improve our understanding of these
pathways, the mRNA expression of enzymes implicated in E2
synthesis and action were evaluated in T47D and MCF7 cell lines.
Our study shows that aromatase is not expressed in T47D and its
expression in MCF7 is negligible compared to those of the 17b-
HSD enzymes, indicating that E2 synthesis in these two cell lines
proceeds mainly by 17b-HSD activities certainly via the steroid
sulfatase pathway. Our results also permit a comparison of the
relative mRNA expression levels of the three sex-hormone
receptors, ERa,E R b and AR, in T47D and MCF7 cells. In both
cell lines, AR and ERa are more highly expressed than ERb with
ERa having the highest expression. In MCF7, AR, the cognate
receptor of dihydrotestosterone (DHT), an androgen that
decreases the estradiol-dependent growth of breast cancer cells
[7,19,20], was 6.8 times less expressed than ERa, whereas the
difference is only 1.5 times in T47D. This suggests that AR-
mediated activities are higher in the latter cell line than in the
former. DHT may thus contribute to the decrease of E2-
dependent growth more efficiently in T47D cells than in MCF7
cells.
In conclusion, the present study reveals that a high number (at
least 164) of proteins (including proteins involved in breast cancer
cell growth regulation) are differentially expressed between the two
most used human breast cancer cell lines, T47D and MCF7. This
suggests that these proteins, listed in Tables 1, 2 and S1, could be
differentially expressed in breast tumors. The list of differentially
expressed proteins generated in the present study may provide
useful information for further studies of breast cancer mechanisms
with T47D and MCF7 as breast cancer cell models.
Supporting Information
Table S1 Additional data of mass spectrometry identi-
fication of proteins in spots up-regulated in or unique to
T47D as compared to MCF7 cell line. The function
description and/or biological process were from the UniProt
database (www.uniprot.org). Spot, spot number; FC, fold change;
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from the 2-D gel experiments; Pep, number of unique peptides; U,
unique. The number after the protein name indicated the
additional spot in which the protein was found.
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